Related Experiment Video
Updated: Aug 12, 2026
Strategies for Study of Neuroprotection from Cold-preconditioning
Published on: September 2, 2010
Neuroprotection
1University Department of Medicine and Therapeutics, Gardiner Institute, Western Infirmary, Glasgow, UK.
Abstract:
Thrombolysis improves stroke outcome, but is applicable to a limited number of patients. Neuroprotection has the prospect to be universally offered, either alone or in combination with thrombolysis. Potential drug targets include elements of the excitotoxic glutamate cascade, calcium entry, intracellular protease activation, free radical damage, the inflammatory response and membrane repair. Clinical trials with many agents have so far been disappointing, but hindsight reveals flaws in the choice of compound, the dose that was administered or trial design. A further crop of trials has recently been initiated or completed, with results expected from 2000 to 2003. More selective, potent or better tolerated neuroprotective strategies are still being developed for clinical use, and approaches to trial conduct are advancing: increased use of computer randomisation algorithms or diffusion-weighted magnetic resonance imaging should improve trial power. The prospects for a safe and effective treatment to improve stroke outcome remain good.
Insights
Neuroprotection offers a promising universal stroke treatment, alone or with thrombolysis. Despite past trial disappointments, ongoing research and improved trial designs enhance prospects for effective neuroprotective therapies.
Area of Science:
- Neuroscience
- Pharmacology
- Clinical Trials
Background:
- Thrombolysis improves stroke outcomes but has limited patient applicability.
- Neuroprotection presents a potential universal treatment strategy for stroke, applicable alone or with thrombolysis.
- Existing neuroprotective agents have faced challenges in clinical trials due to issues with compound selection, dosage, and trial design.
Purpose of the Study:
- To review the potential of neuroprotection as a stroke treatment.
- To identify key molecular targets within neuroprotection strategies.
- To discuss advancements in clinical trial methodologies for neuroprotective agents.
Main Methods:
- Review of existing literature on neuroprotection in stroke.
- Analysis of past clinical trial outcomes and identified limitations.
- Discussion of emerging neuroprotective agents and advanced trial designs.
Main Results:
- Several molecular pathways, including excitotoxicity and calcium signaling, are potential targets for neuroprotection.
- Past clinical trials yielded disappointing results, often attributed to suboptimal drug choice, dosage, or trial design.
- Newer trials are employing more selective agents and improved methodologies like computer randomization and diffusion-weighted MRI.
Conclusions:
- Despite past setbacks, the development of safe and effective neuroprotective treatments for stroke remains a strong possibility.
- Advancements in drug development and clinical trial conduct are expected to improve the success rate of neuroprotective therapies.
- The future prospects for improving stroke outcomes with neuroprotection are optimistic.
Related Concept Videos
00:49The Blood-brain Barrier
01:15Neurogenesis and Regeneration of Nervous Tissue